Clinical Trial Update: Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating galantamine for cognitive impairments in schizophrenia and schizoaffective disorder; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Galantamine (galantamine)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED | Results posted: 2020-12-16